CorMedix Inc. (CRMD) Appoints New Chief Medical Officer, Mark A. Klausner, M.D
CorMedix, Inc., a developmental-stage biopharmaceutical company, announced the appointment of a new Chief Medical Officer (CMO), Mark A. Klausner, M.D. Dr. Klausner has over 25 years of pharmaceutical experience in various functional and therapeutic areas, which includes comprehensive experience in the areas of nephrology and cardiovascular therapeutic areas. Dr. Klausner joins the CorMedix team from Nephrogenex, Inc., a developmental biotechnology corporation, where he acted as Chief Medical Officer since 2007. Dr. Klausner held the responsibility to strategize and execute Nephrogenex’s clinical trials and regulatory compliance, which includes its submissions and correspondence with the Food and Drug Administration (FDA). Preceding Nephrogenex,…